SLCO1B1 Variant (Val174Ala) Test

Statins are the most widely prescribed cholesterol-lowering drugs in the world, and most people tolerate them without problems. But a significant minority develop muscle pain, weakness, or in rare cases, serious muscle damage. For decades, doctors had no reliable way to predict who would suffer these side effects and who would not. This test changes that. It reads a single spot in your DNA that controls how quickly your liver pulls statins out of your blood, and the answer can reshape which statin you take, at what dose, and whether you need closer monitoring.

The SLCO1B1 Val174Ala variant (also called c.521T>C or rs4149056) is a one-letter change in the gene that builds a liver transporter protein called OATP1B1. This transporter sits on the surface of liver cells and acts like a dock, pulling statins and other compounds out of your bloodstream and into the liver where they do their work. If you carry this variant, that dock is impaired, and statins linger in your blood longer than they should, reaching concentrations that can damage muscle tissue.

How This Variant Affects Your Body

The OATP1B1 transporter is found exclusively on liver cells, specifically on the side of the cell that faces the bloodstream. Under normal conditions, it grabs statins and other molecules from the blood and shuttles them into the liver for processing and elimination. The Val174Ala variant disrupts the transporter's ability to reach the cell surface properly, reducing its transport capacity by more than 90% compared to the normal version of the protein.

The result is straightforward: drugs that depend on this transporter stay in your blood at higher concentrations for longer periods. For statins, this means your muscles are exposed to more drug than your liver intended. It also means the statin spends less time inside the liver, which is the only place it actually lowers cholesterol. So you may get less cholesterol benefit and more side-effect risk at the same dose as someone without the variant.

Beyond statins, this transporter handles a range of substances your body produces naturally, including bilirubin (the yellow pigment your liver processes from old red blood cells), bile salts, and certain hormones. People who carry this variant sometimes have mildly elevated bilirubin levels as a consequence.

Statin Myopathy Risk

The connection between this variant and statin-related muscle problems is one of the strongest gene-drug links in all of medicine. The landmark SEARCH trial, a genome-wide study of patients taking 80 mg of simvastatin daily, found that carrying one copy of the variant (the TC genotype) increased the odds of developing myopathy by about 4.5 times. Carrying two copies (the CC genotype) raised the odds roughly 17-fold. More than 60% of the myopathy cases in that trial could be traced back to this single genetic variant.

A meta-analysis pooling 14 studies in European populations confirmed these findings across broader groups of statin users. People with the CC genotype were about 3 times as likely to develop myopathy, and those with the TC genotype were about 1.6 times as likely, compared to people with the normal TT genotype. When the analysis focused on simvastatin specifically, the pattern held, with CC carriers at roughly 2.8 times the risk and TC carriers at about 1.8 times the risk.

The risk is not equal across all statins. Simvastatin poses the greatest risk because it relies most heavily on the OATP1B1 transporter for liver uptake. Atorvastatin carries moderate risk. Pravastatin, rosuvastatin, fluvastatin, and pitavastatin are affected far less, because they either use different transport routes into the liver or are cleared through other pathways. This statin-specific gradient is the reason pharmacogenetic guidelines do not simply say "avoid all statins" if you carry the variant. They guide you toward the safer options.

Pharmacokinetic Impact: What Happens to Drug Levels

The difference in drug exposure between genotypes is dramatic. A genome-wide pharmacokinetic study found that people with two copies of the variant (CC, classified as "poor function") had a 273% increase in the amount of active simvastatin circulating in their blood compared to people with normal function. Those with one copy (TC, "decreased function") had about a 40% increase. On the other end, some rare variants in the same gene actually speed up transport, reducing drug exposure by as much as 67%.

These numbers explain why muscle problems cluster in variant carriers. Statin-induced myopathy is a dose-dependent side effect. If your body handles a 40 mg dose as though it were effectively a much higher dose, your muscles bear the consequences.

Does This Variant Affect Heart Disease Outcomes?

A reasonable next question is whether carrying this variant, and the reduced statin effectiveness it may cause, translates into worse cardiovascular outcomes. The largest study to examine this enrolled about 3,000 high-risk patients undergoing cardiac catheterization and followed them for six years. Carriers of the variant did have modestly higher LDL cholesterol (about 6.2 mg/dL higher per copy of the C allele). But there was no detectable difference in rates of death or heart attack between carriers and non-carriers.

A systematic review examining 37 studies reached a similar conclusion: no study has demonstrated that SLCO1B1 testing leads to improved cardiovascular events. The variant's clinical impact runs primarily through side effects, not through heart disease risk itself. This is an important distinction. The test helps you tolerate statin therapy by guiding drug selection, not by predicting whether you will have a heart attack.

Genotype Categories and What They Mean

Your result will be reported as a genotype (TT, TC, or CC) and translated into a functional category. These categories, standardized by the Clinical Pharmacogenetics Implementation Consortium (CPIC), directly determine which statins and doses are recommended for you.

These recommendations come from CPIC and the Dutch Pharmacogenetics Working Group (DPWG), the two major bodies that issue pharmacogenetic prescribing guidelines. The DPWG classifies preemptive SLCO1B1 testing as "essential" before prescribing simvastatin at 80 mg per day, "beneficial" for simvastatin up to 40 mg per day, and "potentially beneficial" for atorvastatin and rosuvastatin.

How Common Is This Variant?

The frequency of the risk-associated C allele varies considerably across ancestral groups. About 15% of people with European ancestry carry at least one copy of the C allele, and roughly 2 to 3% are homozygous (CC). The variant is most common in Native American populations (around 24 to 28% allele frequency) and least common in sub-Saharan African populations (about 2 to 6%). East Asian and Middle Eastern populations fall in between, at roughly 10 to 15%.

One significant equity gap in current testing: recent research has identified additional SLCO1B1 variants common in people with African ancestry (such as rs59502379) that also affect statin myopathy risk but are not yet included in most standard pharmacogenetic panels. If you have African ancestry and test negative for Val174Ala, that does not necessarily mean you are free of SLCO1B1-related statin risk.

A One-Time Test

Unlike nearly every other biomarker on this site, SLCO1B1 is a genetic test, not a blood-level measurement. Your genotype is fixed at conception and does not change with age, diet, exercise, illness, or medication. You need this test exactly once in your lifetime, and the result is permanent.

That said, the value of knowing your genotype can grow over time. Statin prescribing decisions may come up multiple times across your lifespan, especially as cardiovascular risk accumulates with age. Having your SLCO1B1 result on file means every future prescribing decision can be informed by it, whether that is your first statin at age 45 or a dose adjustment at age 70. Getting tested once eliminates guesswork for every encounter after.

If you are already taking a statin without problems, your result still has value. Knowing you carry the variant could prompt a switch to a safer statin at a comparable dose, reducing your long-term risk of muscle problems that sometimes develop after months or years of use. If your result shows normal function, you gain confidence that your current regimen is appropriate from a genetic standpoint.

Factors That Compound Genetic Risk

Carrying the Val174Ala variant does not guarantee you will develop muscle problems on a statin. It raises your risk, and that risk is further amplified by other factors. Being female, being over 65, having impaired kidney function, having an underactive thyroid, and taking medications that compete for the same liver transporter or that slow statin metabolism (such as certain antifungals, antibiotics, or immunosuppressants) all independently increase the chance of statin-related muscle injury. When one or more of these factors layer on top of the genetic variant, the combined risk can be substantially higher than either factor alone.

The interaction between SLCO1B1 and other genes matters too. Variants in CYP3A4 (a liver enzyme that breaks down simvastatin and atorvastatin) and ABCG2 (another transporter that affects rosuvastatin levels) can independently alter drug exposure. A pharmacogenetic panel that tests all three genes gives a more complete picture than SLCO1B1 alone.